Trial · Interventional
RecruitingPhase 1Registry dataAssessing the Safety and Tolerability of NMN in DHDDS-CDG
Overview
- Status
- Recruiting
- Phase
- Phase 1
- Enrollment
- 8 participants (estimated)
- Sponsor
- Eva Morava-Kozicz · Other
- Design
- Allocation not applicable · Open label (no masking)
- Countries
1 country
United States
- Start
- 8 May 2026
- Primary completion
- 1 Aug 2027 (estimated)
- Completion
- 1 Aug 2027 (estimated)
- First posted
- 7 May 2026
- Last update posted
- 22 Jun 2026
- Conditions
- DHDDS-Congenital Disorder of Glycosylation · DHDDS-CDG · Congenital Disorder of Glycosylation
Timeline
1 trial · 1 ongoing
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 1
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Interventions
- Nicotinamide Mononucleotide (NMN) NucleosidaseDrug
Arms1
Experimental
nicotinamide mononucleotide (NMN)
Participants will take 250mg NMN daily.
Primary outcomes1
Outcomes the sponsor listed as primary.
Incidence of adverse events (AEs)
Time frame · up to 12 months
Registry description
Incidence of AEs will be collected throughout the treatment period and optional long-term safety follow up period.
Secondary outcomes(3)
International Cooperative Ataxia Rating Scale (ICARS) Score
Time frame · Baseline, 6 months, 12 months
Registry description
Change in ICARS score from baseline to end of the treatment period (6 months) and long term follow up (12 months). The minimal score is 0 and the maximum score is 100, with a higher score indicating greater impairment as a result of ataxia.
Composite gait stability score (Cord walking test performance)
Time frame · Baseline, 6 months, 12 months
Registry description
Cord walking performance will be quantified using a standardized video-based computer vision pipeline applied to semi-structured recordings of participants walking along a straight line. Markerless pose estimation algorithms will extract time-resolved body keypoints, from which predefined gait and postural metrics will be derived, including step width variability, step length consistency, lateral deviation from the walking path, and trunk instability (e.g., standard deviation of body lean). Each metric will be summarized per recording and combined into a composite gait stability score using a prespecified algorithm. Change from baseline to 6 and 12 months will be calculated as within-subject differences in these quantitative measures, enabling objective assessment of gait abnormalities over time.
Composite tremor severity score (Archimedes spiral test performance)
Time frame · Baseline, 6 months, 12 months
Registry description
Archimedes spiral test performance will be quantified using standardized digital analysis of recorded spiral drawings. Video or image inputs will be processed to extract the drawn trajectory, and quantitative features of tremor and motor control will be computed, including line deviation from an ideal spiral template, tremor amplitude (spatial variability), frequency of oscillations, and drawing smoothness (e.g., velocity and jerk metrics). These features will be aggregated into a composite tremor severity score using a predefined scoring framework. Change from baseline to 6 and 12 months will be assessed as within-subject differences in these quantitative metrics, providing an objective measure of hand tremor severity and progression.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 4 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.